Literature DB >> 11042491

Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11.

A P Dubnovitsky1, Z I Kravchuk, A A Chumanevich, A Cozzi, P Arosio, S P Martsev.   

Abstract

Expression of the VL-domain of mouse monoclonal antibody F11 to human spleen ferritin in Escherichia coli cells is associated with the formation of insoluble protein aggregates (inclusion bodies). The aggregates were solubilized in the presence of guanidine hydrochloride and the recombinant VL-domain was purified by immobilized metal affinity chromatography (IMAC). Subsequent renaturation results in approximately 99% pure preparation with high yield. The VL-domain forms dimers at concentrations from 1 to 10 mg/ml. Monomeric form is detected only at protein concentrations below 0.5 mg/ml. Functional activity of the VL-domain was verified by two variants of ELISA. The affinity of the VL-domain ((0.2-1.2). 108 M(-1)) is similar to the affinity of the full-length parental antibody F11 because when the immobilized VL-domain was used, the binding constant of ferritin to the VL-domain was only 4-6-fold lower than that in the case of F11 antibody. In another ELISA system with immobilized ferritin, affinity was decreased 30-fold. The VL-domain of antibody F11 is the first example of the recombinant variable domain of the immunoglobulin light chain that preserves the antigen-binding activity in the absence of the partner VH-domain. The data indicate that the recombinant VL-domain can be used in construction of chimeric immunotoxins and other antigen-binding proteins in immunotherapy and in studies of correlations between folding, stability, and activity of immunoglobulins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042491

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  5 in total

1.  The 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimer.

Authors:  Katerina Sidera; Avraam El Hamidieh; Avgi Mamalaki; Evangelia Patsavoudi
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

Review 2.  The structural basis of antibody-antigen recognition.

Authors:  Inbal Sela-Culang; Vered Kunik; Yanay Ofran
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

3.  Effect of Single Amino Acid Substitutions by Asn and Gln on Aggregation Properties of Bence-Jones Protein BIF.

Authors:  Maria Timchenko; Azat Abdullatypov; Hiroshi Kihara; Alexander Timchenko
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

4.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

5.  Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies.

Authors:  Tetyana Dashivets; Jan Stracke; Stefan Dengl; Alexander Knaupp; Jan Pollmann; Johannes Buchner; Tilman Schlothauer
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.